Skip Navigation



European Heart Journal Advance Access published online on November 30, 2004
European Heart Journal, doi:10.1093/eurheartj/ehi028
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
26/3/263    most recent
ehi028v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paraskevaidis, I. A.
Right arrow Articles by Kremastinos, D. Th.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paraskevaidis, I. A.
Right arrow Articles by Kremastinos, D. Th.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical research

Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance

Ioannis A. Paraskevaidis 1*, Efstathios K. Iliodromitis 1, Demetrios Vlahakos 2, Dimitrios P. Tsiapras 1, Athanassios Nikolaidis 3, Aikaterini Marathias 3, Alkiviadis Michalis 4, and Dimitrios Th. Kremastinos 1

1 2nd Department of Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou Avenue, 176 74 Athens, Greece
2 Department of Nephrology, Onassis Cardiac Surgery Center, Athens, Greece
3 Coronary Care Unit and Anesthesiology, Onassis Cardiac Surgery Center, Athens, Greece
4 2nd Department of Cardiac Surgery, Onassis Cardiac Surgery Center, Athens, Greece

* To whom correspondence should be addressed.
Ioannis A. Paraskevaidis, E-mail: elbee{at}ath.forthnet.gr or iparas@otenet.gr


  Abstract

Aims Previous reports have demonstrated enhanced myocardial protection and better post-ischaemic recovery using the oxygen free radical scavenger deferoxamine (DEF) during cardioplegia. The aim of this study was to test whether, in patients undergoing coronary artery bypass grafting (CABG), DEF i.v. infusion can reduce reperfusion injury on a short- and long-term basis.

Methods and results Forty-five consecutive male patients were randomly allocated to two groups: in group D (n = 25, age 60.8 ± 8.6 years), 4g of DEF were infused for 8 h starting immediately after the induction of anaesthesia; in group C (n = 20, age 62.2 ± 6.4 years) dextrose solution was given for the same time as placebo. Haemodynamic monitoring and measurement of oxygen free radical production [by measuring thiobarbituric acid reactive substances (TBARS)] were carried out before and after CABG. Left ventricular ejection fraction (EF) and wall motion score index (WMSI) were measured before and after CABG and 12 months later. Haemodynamic measurements were similar in both groups before and after CABG. TBARS peaked at 4.8 ± 1.1nmol/mL in group C, but remained unchanged (2.4 ± 0.9nmol/mL) in group D (P = 0.01). At baseline, both the EF and WMSI were similar between the groups. Following CABG, EF increased more in group D (8.8 ± 8.4%) than in group C (1.3 ± 6.7%), P = 0.008, while WMSI decreased more in group D (-0.7 ± 0.3) than in group C (-0.2 ± 0.2), P = 0.0001. Dividing group D according to the pre-operative median EF value (38%), we observed that after 1 year follow-up, DEF infusion conferred more protection in patients with a lower EF (EF increased by 19.3 ± 6.2%, WMSI decreased by -1.1 ± 0.2) than in those with a higher EF (EF increased by 7.7 ± 4.5%, WMSI decreased by -0.8 ± 0.2), P = 0.001, respectively.

Conclusion In patients undergoing CABG, DEF i.v. infusion ameliorates oxygen free radical production and protects the myocardium against reperfusion injury. Patients with a lower EF seem to benefit more by DEF i.v. infusion.

Keywords: Reperfusion injury; Free radicals; Cardioprotection; Stunned myocardium.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 StrokeHome page
M. Selim
Deferoxamine Mesylate: A New Hope for Intracerebral Hemorrhage: From Bench to Clinical Trials
Stroke, March 1, 2009; 40(3_suppl_1): S90 - S91.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Milei, P. Forcada, C. G. Fraga, D. R. Grana, G. Iannelli, M. Chiariello, I. Tritto, and G. Ambrosio
Relationship between oxidative stress, lipid peroxidation, and ultrastructural damage in patients with coronary artery disease undergoing cardioplegic arrest/reperfusion
Cardiovasc Res, March 1, 2007; 73(4): 710 - 719.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. R. Zacharski, B. K. Chow, P. S. Howes, G. Shamayeva, J. A. Baron, R. L. Dalman, D. J. Malenka, C. K. Ozaki, and P. W. Lavori
Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial Disease: A Randomized Controlled Trial
JAMA, February 14, 2007; 297(6): 603 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
L. M Yunker, J. S Parboosingh, H. E Conradson, P. Faris, P. J Bridge, J. Buithieu, L. M Title, F. Charbonneau, S. Verma, E. M Lonn, et al.
The effect of iron status on vascular health
Vascular Medicine, May 1, 2006; 11(2): 85 - 91.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Philipp, L. Cui, B. Ludolph, M. Kelm, R. Schulz, M. V. Cohen, and J. M. Downey
Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H450 - H457.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.